Endovascular Engineering (E2), a medical device company advancing clot removal technologies for venous thromboembolism (VTE), has named Dan Rose as CEO. Former CEO and founding team member Mike Rosenthal will continue as chief operating officer and remain on the company's board of Directors. He will also continue in his role as founder and general partner at Inventure Group, where E2 was incubated.
The company's Hēlo Thrombectomy System removes clots with its patented dual-action approach that simultaneously combines aspiration with advanced mechanical clot disruption. The dual-action mechanism occurs within a self-expanding funnel, as the high-speed agitator actively engages and removes the clot under physician-controlled suction. This approach is designed to efficiently and effectively extract clots of mixed morphology. According to the company, Hēlo operates with the agility of a small profile catheter yet boasts the capabilities of a large bore device in a single-pass operation, redefining thrombectomy.
Rose previously served as CEO of LimFlow S.A., a pioneer in limb salvage for patients with chronic limb-threatening ischemia (CLTI). He joined LimFlow as the first employee and successfully guided the company through its acquisition by Inari Medical. He assembled a world-class team that developed and commercialized a practice-changing therapy for the treatment of late-stage CLTI, which resulted in an FDA approval and a landmark publication in the New England Journal of Medicine.
"Under Mike [Rosenthal]'s leadership, the team has achieved remarkable milestones, positioning E2 to successfully complete its ENGULF pivotal trial and advance towards 510(k) clearance from the FDA," said Rose. "I am deeply honored to lead this talented team with the mission of establishing the Hēlo™ PE Thrombectomy System as the preferred option for pulmonary embolism (PE) treatment."
In February 2024, E2 treated it's first subject with the Hēlo PE Thrombectomy System at Tennova Turkey Creek Medical Center in Farragut, Tennessee.
